CEO SUMMARY: Instead of our annual review of key speakers as a source of emerging trends and common themes, this year we assess the attitudes, opinions, and activities of the pathologists, laboratory administrators, managers, and industry executives in attendance at the 15th Annual Executive War College. These people are the grass roots of laboratory medicine
Tag: diagnostic market
CEO SUMMARY: Presented here are THE DARK REPORT’S “Ten Biggest Lab Stories of 2006.” Compared to earlier years, 2006 was not transformative for the laboratory industry. But it was an eventful year, particularly influenced by Siemens’ decision to acquire DPC and Bayer Diagnostics, along with the decision by UnitedHealth Group to grant an exclusive national
PROTEOMICS IS EXPECTED TO BE ONE of the most active areas in molecular diagnostics and Bio-Rad Laboratories, Inc. has just staked a major claim to a promising proteomic technology.
In a transaction announced on August 18, 2006, Bio-Rad will acquire the proprietary proteomics instrument business of Ciphergen Biosystems Inc., which includes the SELDI technology (Surface Enhanced
Lots of news unfolding across the lab industry. Here’s a round-up of recent and noteworthy items:
• Persistent rumors indicate that a new national anatomic pathology company is in formation. Likely to be involved is James New, former CEO of AmeriPath, Inc. during its formative years and through that company’s sale to Welsh Carson Anderson & Stowe in early 2003. (See
CEO SUMMARY: It is no coincidence that another public company is shifting its business focus and expanding its efforts to capture cancer-related anatomic pathology specimens. Demographic trends predict a steady increase in the number of new cancer cases yearly, while new technologies are giving physicians more effective ways to detect cancer and treat it. That
CEO SUMMARY: This exclusive intelligence briefing predicts how specific new technologies may drive changes in the laboratory-testing marketplace during the next five years. The key message is that change is expected to be incremental, not disruptive—given the technology known to be in development at this time. But the more provocative insight relates to how even
ACTIVITY AT DYNACARE HINTS AT POSSIBLE SALE, LABCORP MAY BE BUYER
With Quest Diagnostics Incorporated snapping up independent lab companies right and left in recent months, the question asked by many is “Where’s Laboratory Corporation of America?”
On the sell side, American Medical Laboratories and Unilab have been acquired by Quest Diagnostics. The largest remaining independent commercial
CEO SUMMARY: With the clinical laboratory industry now enjoying growing interest by professional investors, THE DARK REPORT traveled to New York City to meet with financial analyst William B. Bonello, of U S Bancorp Piper Jaffray. Bonello co-authored a just-released overview of what he calls the “diagnostic services industry.” He is bullish on the future
DECEMBER 7, 1999 WAS NOT an auspicious day for Hoffmann-LaRoche. One of its patents related to the PCR testing process was ruled invalid by a Federal District Court.
The ruling involved Roche’s ’818 Taq patent, an enzyme used in the PCR process. The Court found that the patent holder had intentionally withheld material information and distorted